International adaptation and use of NCCN Guidelines.
暂无分享,去创建一个
[1] T. Molina,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.
[2] C. Copie-Bergman,et al. R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B , 2011 .
[3] A. Bazarbachi,et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Zelenetz,et al. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] A. Zelenetz,et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Tomonaga,et al. Long-term study of indolent adult T-cell leukemia-lymphoma. , 2007, Blood.
[7] M. Shimoyama. Treatment of patients with adult T-cell leukemia-lymphoma: an overview , 1992 .